Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01942837 · ClinicalTrials.gov registry record · Phase 2
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 5
- Study locations
NCT01942837 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 67 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (66% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT01942837, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with chemotherapy. The purpose of this study is to analyze features of tumor specimens sampled prior to therapy and at disease progression to determine why patients respond or stop responding to treatment with Enzalutamide. Prior chemotherapy is not a requirement of this trial.
Conditions Studied
Interventions
- DRUG Enzalutamide
Study Locations (5)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- South Shore Hospital - Weymouth
Washington
- University of Washington Medical Center/Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2013-09-13 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01942837
The ClinicalTrials.gov registry entry for NCT01942837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (66% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Enzalutamide is the first listed.
NCT01942837 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT01942837 about?
NCT01942837 is a clinical study titled "Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer". This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with chemotherapy. The purpose of this study is to analyze features of tumor spec...
What is the current status of trial NCT01942837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2013-09-13. Estimated completion is 2022-09-30.
What conditions does trial NCT01942837 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT01942837?
The interventions under investigation include: Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT01942837?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01942837 being conducted?
This trial has 5 study locations across Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RECRUITING · Phase 2
-
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
RECRUITING · Phase 2
-
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.